Informa Pharma introduces AI platform to enhance trial timelines
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Informa Pharma introduces AI platform to enhance trial timelines

17 Jun 2021 (Last Updated June 17th, 2021 12:15)

The AI platform’s machine learning engine facilitates enrolment forecasts at the site, country and overall trial level.

Informa Pharma introduces AI platform to enhance trial timelines
The platform merges its data sets with machine learning capabilities. Credit: Gerd Altmann from Pixabay.

Informa Pharma Intelligence has introduced an artificial intelligence (AI)-based platform called Citeline Study Feasibility to expedite clinical trial decisions and timelines.

Designed to provide predictive analytics, the platform integrates its data sets with machine learning capabilities.

Trial feasibility and analytics teams can leverage the platform to simulate feasibility situations and boost enrolment potential for success over the long term, the company noted.

Referring to a recent study, Informa Pharma said about 85% of trials do not retain patients required to conduct a successful study and more than 90% of trials fail to meet their fixed completion deadlines.

Citeline Study Feasibility can address these challenges by delivering predictive insights optimised for trial site allocation and scoring. These insights also estimate enrolment duration and the overall possibility of enrolment success.

The machine learning engine of the platform enables enrolment forecasts at the site, country and overall trial level.

Based on these predictions, users can plan trial participation and fast-track the first patient enrolment.

The visual analyses of these scenarios generated by the platform allow understanding of trial design elements that positively or negatively impact enrolment timelines.

Users can optimise, compare and share the feasibility scenarios.

Informa Pharma Intelligence chief product and technology officer Nicky Marlin said: “The recent high-profile Covid-19 clinical trials demonstrated truly how important accelerated trial timelines can be to drug development.

“But too often, potentially lifesaving therapies encounter detrimental roadblocks in the form of incompatible sites and low clinical trial enrolment.

“Citeline Study Feasibility is uniquely positioned to take the manual effort out of the clinical trial planning process and give the industry the tools it needs to lower costs and make informed decisions for each study.”

In September last year, Australian company Opyl developed new software that can forecast the outcomes of Covid-19 clinical trials using artificial intelligence (AI).